

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5203962

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	MORPHOTEK, INC.	09/26/2018
RECEIVING PARTY DATA		
Name:	EISAI INC.	
Street Address:	100 TICE BOULEVARD	
City:	WOODCLIFF LAKE	
State/Country:	NEW JERSEY	
Postal Code:	07677	
PROPERTY NUMBERS Total: 6		
Property Type	Number	
Application Number:	60674185	
Application Number:	11410442	
Application Number:	13356724	
Application Number:	14809887	
Application Number:	15346332	
Application Number:	12503983	
CORRESPONDENCE DATA		
Fax Number:	(215)568-3439	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	2155683100	
Email:	assignments@woodcock.com	
Correspondent Name:	BAKER & HOSTETLER LLP	
Address Line 1:	2929 ARCH STREET	
Address Line 2:	12TH FLOOR, CIRA CENTRE	
Address Line 4:	PHILADELPHIA, PENNSYLVANIA 19104	
ATTORNEY DOCKET NUMBER:	104018 - MORR-027	
NAME OF SUBMITTER:	FAITH A. POORE	
SIGNATURE:	/Faith A. Poore/	
DATE SIGNED:	10/24/2018	

Total Attachments: 12

source=Assignment_executed_MORR_027_MOR_to_Eisai#page1.tif
source=Assignment_executed_MORR_027_MOR_to_Eisai#page2.tif
source=Assignment_executed_MORR_027_MOR_to_Eisai#page3.tif
source=Assignment_executed_MORR_027_MOR_to_Eisai#page4.tif
source=Assignment_executed_MORR_027_MOR_to_Eisai#page5.tif
source=Assignment_executed_MORR_027_MOR_to_Eisai#page6.tif
source=Assignment_executed_MORR_027_MOR_to_Eisai#page7.tif
source=Assignment_executed_MORR_027_MOR_to_Eisai#page8.tif
source=Assignment_executed_MORR_027_MOR_to_Eisai#page9.tif
source=Assignment_executed_MORR_027_MOR_to_Eisai#page10.tif
source=Assignment_executed_MORR_027_MOR_to_Eisai#page11.tif
source=Assignment_executed_MORR_027_MOR_to_Eisai#page12.tif

ASSIGNMENT

WHEREAS, **Morphotek, Inc.**, hereinafter referred to as the ASSIGNOR, having its principal place of business at **210 Welsh Pool Road, Exton, Pennsylvania 19341** is the owner of certain inventions or improvements for which applications for Letters Patent have been made or for which Letters Patent have been issued, all of which are listed on Attachment A hereto (hereafter Patent Property); and

WHEREAS, **Eisai Inc.**, hereinafter referred to as the ASSIGNEE, having its principal place of business at **100 Tice Blvd., Woodcliff Lake, NJ 07677**, is desirous of acquiring the entire right, title and interest in and to the said Patent Property in any and all countries;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, and intending to be legally bound hereby, ASSIGNOR has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over to said ASSIGNEE, the entire right, title and interest in and to said Patent Property and any and all continuations, divisions and renewals of and substitutes for said Patent Property and to and under any and all additional Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and the full right to sue for and recover damages recoverable for past infringement of the same, and for violations of provisional rights having arisen from any published application(s) for said Patent Property. ASSIGNOR further assigns to and authorizes said ASSIGNEE to file corresponding applications for Letters Patent in all countries, to be held and enjoyed by said ASSIGNEE, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, sale and transfer not been made.

It is hereby covenanted that ASSIGNOR has full right to convey the entire interest herein assigned, and that ASSIGNOR has not executed and will not execute any agreement in conflict herewith, and ASSIGNOR further covenants and agrees that it will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said Patent Property in said assignee, its successors, assigns, nominees, or legal representatives, and ASSIGNOR agrees to communicate to said ASSIGNEE or to its nominee all known facts respecting said Patent Property, to testify in any legal proceedings, to sign all lawful papers to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything reasonably possible to aid said ASSIGNEE, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries, all at the expense, however, of said ASSIGNEE, its successors, assigns, nominees or legal representatives.


Morphotek to Eisai Inc.

AND ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue to said ASSIGNEE, as assignee of the entire right, title and interest, any and all Letters Patent for said Patent Property, including any and all Letters Patent of the United States which may be issued and granted on or as a result of any applications included in said Patent Property, in accordance with the terms of this assignment.

Morphotek to Eisai Inc.

IN WITNESS WHEREOF, the undersigned, being properly authorized to execute this Assignment, hereunto sets their hand and seal.

Morphotek, Inc.



By: Shuhei Shimizu
Shuhei Shimizu

Its: Vice President, Business Development,
IP & Alliance Management

Date: Sep 26, 2018

STATEMENT OF NOTARY PUBLIC

STATE OF Pennsylvania :

: SS

COUNTY OF Chester :

On this 26 day of September, year of 2018, before me personally came the above named **Shuhei Shimizu** to me personally known and known to me to be the same individual who executed the foregoing assignment, and who acknowledged to me that execution of the same was of that person's own free will for the use and purposes therein set forth.

Thomas W. Apple
Notary Public

Morphotek to Eisai Inc.

IN WITNESS WHEREOF, the undersigned, being properly authorized to execute this Assignment, hereunto sets their hand and seal.

Eisai Inc.

By: Maureen A. Bresnahan
Maureen Bresnahan

Its: Assistant Secretary

Date: 16 October 2018

STATEMENT OF NOTARY PUBLIC


STATE OF MA _____:

: SS

COUNTY OF Essex _____:

On this 16th day of October, year of 2018, before me personally came the above named **Maureen Bresnahan** to me personally known and known to me to be the same individual who executed the foregoing assignment, and who acknowledged to me that execution of the same was of that person's own free will for the use and purposes therein set forth.

Mary M. Schwartz
Notary Public



Morphotek to Eisai Inc.

ATTACHMENT A

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-026-PIUS	United States	60/544,364	02/12/2004	Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-UIPC	Patent Cooperation Treaty	PCT/US2005/004240	02/11/2005	Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1US	United States	11/056,776	02/11/2005	Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-C1US	United States	13/826,964 9,650,440	03/14/2013 05/16/2017	Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-D1US	United States	12/500,144 9,624,297	07/09/2009 04/18/2017	Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-D2US	United States	15/454,412	03/07/2017	Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1AU	Australia	2005214331 2005214331	02/11/2005 01/05/2012	Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-D1AU	Australia	2011253933 2011253933	12/09/2011 04/26/2013	Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-D2AU	Australia	2013202884 2013202884	04/08/2013 01/07/2016	Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-D3AU	Australia	2015268693 2015268693	12/14/2015 04/27/2017	Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-D4AU	Australia	2017202341	02/11/2005	Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1CA	Canada	2,556,027 2,556,027	02/11/2015 11/24/105	Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1EP	European Patent Convention	05722917.1	02/11/2005	Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1AT	Austria	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1BE	Belgium	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen

Morphotek to Eisai Inc.

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-026-U1BG	Bulgaria	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1CY	Cyprus	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1CZ	Czech Republic	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1DK	Denmark	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1EE	Estonia	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1FI	Finland	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1FR	France	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1GB	United Kingdom	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1DE	Germany	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1GR	Greece	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1HU	Hungary	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1IS	Iceland	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1IE	Ireland	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1IT	Italy	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1LT	Lithuania	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1LU	Luxembourg	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen

Morphotek to Eisai Inc.

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-026-U1MC	Monaco	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1NL	Netherlands	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1PL	Poland	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1PT	Portugal	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1RO	Romania	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1SI	Slovenia	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1SK	Slovakia	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1ES	Spain	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1SE	Sweden	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1CH	Switzerland	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1TR	Turkey	05722917.1		Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-U1JP	Japan	2006-553229 4805848	02/11/2005 08/19/2011	Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-D1EP	European Patent Convention	10183459.6	02/11/2005	Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-D2EP	European Patent Convention	15154029.1	02/11/2015	Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-026-D3EP	European Patent Convention	16180435.6	02/11/2005	Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
MORR-027-P1US	United States	60/674,185	04/22/2005	Antibodies With Immune Effector Acti That Internalize in Folate Receptor Alp Positive Cells

Morphotek to Eisai Inc.

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-027-U1PC	Patent Cooperation Treaty	PCT/US2006/016004	04/24/2006	Antibodies With Immune Effector Activity And That Internalize in Folate Receptor Alpha Positive Cells
MORR-027-U1US	United States	11/410,442	04/24/2006	Antibodies With Immune Effector Activity And That Internalize in Folate Receptor Alpha Positive Cells
MORR-027-C1US	United States	13/356,724 9,144,614	01/24/2012 09/29/2015	Antibodies With Immune Effector Activity And That Internalize in Folate Receptor Alpha Positive Cells
MORR-027-C2US	United States	14/809,887 9,522,195	07/27/2015 12/20/2016	Antibodies With Immune Effector Activity And That Internalize in Folate Receptor Alpha Positive Cells
MORR-027-C3US	United States	15/346,332	11/08/2016	Antibodies With Immune Effector Activity And That Internalize in Folate Receptor Alpha Positive Cells
MORR-027-D1US	United States	12/503,983 8,124,083	07/16/2009 02/28/2012	Antibodies With Immune Effector Activity And That Internalize in Folate Receptor Alpha Positive Cells
MORR-027-U1AU	Australia	2006241099 2006241099	04/24/2006 08/02/2012	Antibodies With Immune Effector Activity And That Internalize in Folate Receptor Alpha Positive Cells
MORR-027-D1AU	Australia	2012205242 2012205242	04/24/2006 06/05/2014	Antibodies With Immune Effector Activity And That Internalize in Folate Receptor Alpha Positive Cells
MORR-027-D2AU	Australia	2014202667 2014202667	05/15/2014 11/19/2015	Antibodies With Immune Effector Activity And That Internalize in Folate Receptor Alpha Positive Cells
MORR-027-D3AU	Australia	2015252130 2015252130	04/24/2006 11/02/2017	Antibodies With Immune Effector Activity And That Internalize in Folate Receptor Alpha Positive Cells
MORR-027-D4AU	Australia	2017239474	04/24/2016	Antibodies With Immune Effector Activity And That Internalize in Folate Receptor Alpha Positive Cells
MORR-027-U1CA	Canada	2,607,444 2,607,444	04/24/2006 03/10/2015	Antibodies With Immune Effector Activity And That Internalize in Folate Receptor Alpha Positive Cells
MORR-027-U1EP	European Patent Convention	06758862.8	04/24/2006	Antibodies With Immune Effector Activity And That Internalize in Folate Receptor Alpha Positive Cells
MORR-027-D1EP	European Patent Convention	09176155.1	11/16/2009	Antibodies With Immune Effector Activity And That Internalize in Folate Receptor Alpha Positive Cells
MORR-027-U1JP	Japan	2008-508006	04/24/2006	Antibodies With Immune Effector Activity And That Internalize in Folate Receptor Alpha Positive Cells
MORR-027-D1JP	Japan	2011-290406	12/29/2011	Antibodies With Immune Effector Activity And That Internalize in Folate Receptor Alpha Positive Cells

Morphotek to Eisai Inc.

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-031-P1US	United States	60/660,177	03/10/2005	Anti-Mesothelin Antibodies
MORR-031-U1PC	Patent Cooperation Treaty	PCT/US2006/008598	03/09/2006	Anti-Mesothelin Antibodies
MORR-031-U1US	United States	11/373,546 7,592,426	03/09/2006 09/22/2009	Anti-Mesothelin Antibodies
MORR-031-C1US	United States	13/476,656 8,481,703	05/21/2012 07/09/2013	Anti-Mesothelin Antibodies
MORR-031-C2US	United States	14/148,011 9,115,197	01/06/2014 08/25/2015	Anti-Mesothelin Antibodies
MORR-031-D1US	United States	12/545,369 8,206,710	08/21/2009 06/26/2012	Anti-Mesothelin Antibodies
MORR-031-D2US	United States	13/799,766 8,658,173	03/13/2013 02/25/2014	Anti-Mesothelin Antibodies
MORR-031-U1AU	Australia	2006223301 2006223301	03/09/2006 02/17/2011	Anti-Mesothelin Antibodies
MORR-031-D1AU	Australia	2011200251 2011200251	03/09/2006 12/06/2012	Anti-Mesothelin Antibodies
MORR-031-D2AU	Australia	2012254877 2012254877	03/09/2006 05/05/2016	Anti-Mesothelin Antibodies
MORR-031-U1CA	Canada	2,600,505 2,600,505	03/09/2006 05/03/2016	Anti-Mesothelin Antibodies
MORR-031-U1EP	European Patent Convention	06737748.1 1861425	03/09/2006 05/16/2012	Anti-Mesothelin Antibodies
MORR-031-U1FR	France	1861425	05/16/2012	Anti-Mesothelin Antibodies
MORR-031-U1DE	Germany	602006029482.4 1861425	05/16/2012	Anti-Mesothelin Antibodies
MORR-031-U1IT	Italy	25591/BE/2012 1861425	05/16/2012	Anti-Mesothelin Antibodies
MORR-031-U1NL	Netherlands	1861425	05/16/2014	Anti-Mesothelin Antibodies
MORR-031-U1ES	Spain	E2386367T3 1861425	05/16/2014	Anti-Mesothelin Antibodies
MORR-031-U1SE	Sweden	1861425	05/16/2014	Anti-Mesothelin Antibodies
MORR-031-U1CH	Switzerland	1861425	05/16/2014	Anti-Mesothelin Antibodies
MORR-031-U1GB	United Kingdom	1861425	05/16/2014	Anti-Mesothelin Antibodies
MORR-031-D1EP	European Patent Convention	10180413.6 2322560	03/09/2006 09/04/2013	Anti-Mesothelin Antibodies
MORR-031-D1FR	France	2322560	09/04/2013	Anti-Mesothelin Antibodies
MORR-031-D1DE	Germany	602006038309.6 2322560	09/04/2013	Anti-Mesothelin Antibodies

Morphotek to Eisai Inc.

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-031-D1IT	Italy	29194/BE/2013 2322560	09/04/2013	Anti-Mesothelin Antibodies
MORR-031-D1NL	Netherlands	2322560	09/04/2013	Anti-Mesothelin Antibodies
MORR-031-D1ES	Spain	2429340 2322560	09/04/2013	Anti-Mesothelin Antibodies
MORR-031-D1SE	Sweden	2322560	09/04/2013	Anti-Mesothelin Antibodies
MORR-031-D1CH	Switzerland	2322560	09/04/2013	Anti-Mesothelin Antibodies
MORR-031-D1GB	United Kingdom	10180413.6 2322560	09/04/2013	Anti-Mesothelin Antibodies
MORR-031-U1JP	Japan	2008-500966 4949373	03/09/2006 03/16/2012	Anti-Mesothelin Antibodies
MORR-031-D1JP	Japan	2011-290449 5378497	12/29/2011 10/04/2013	Anti-Mesothelin Antibodies
MORR-031-D2JP	Japan	2013-168325 5788443	08/13/2013 08/07/2015	Anti-Mesothelin Antibodies
MORR-035-P1US	United States	61/394,812	10/20/2010	Anti-Folate Receptor Alpha Antibody Glycoforms
MORR-035-U1WO	Patent Cooperation Treaty	PCT/US2011/056966	10/19/2011	Anti-Folate Receptor Alpha Antibody Glycoforms
MORR-035-U1US	United States	13/277,161	10/19/2011	Anti-Folate Receptor Alpha Antibody Glycoforms
MORR-035-U1AU	Australia	2011317088 2011317088	10/19/2011 05/05/2016	Anti-Folate Receptor Alpha Antibody Glycoforms
MORR-035-D1AU	Australia	2016202082	04/04/2016	Anti-Folate Receptor Alpha Antibody Glycoforms
MORR-035-U1BR	Brazil	1120130092750	10/19/2011	Anti-Folate Receptor Alpha Antibody Glycoforms
MORR-035-U1CA	Canada	2,815,080	10/19/2011	Anti-Folate Receptor Alpha Antibody Glycoforms
MORR-035-U1CN	China	201180050383.8	10/19/2011	Anti-Folate Receptor Alpha Antibody Glycoforms
MORR-035-U1EP	European Patent Convention	11835098.2	10/19/2011	Anti-Folate Receptor Alpha Antibody Glycoforms
MORR-035-U1IL	Israel	225579	10/19/2011	Anti-Folate Receptor Alpha Antibody Glycoforms
MORR-035-U1IN	India	2666/DELNP/2013	10/19/2011	Anti-Folate Receptor Alpha Antibody Glycoforms
MORR-035-U1JP	Japan	2013-535058	10/19/2011	Anti-Folate Receptor Alpha Antibody Glycoforms
MORR-035-U1KR	South Korea	10-2013-7012669	10/19/2011	Anti-Folate Receptor Alpha Antibody Glycoforms
MORR-035-U1MX	Mexico	MX/a/2013/004202	10/19/2011	Anti-Folate Receptor Alpha Antibody Glycoforms

Morphotek to Eisai Inc.

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-035-D1MX	Mexico	MX/a/2016/014116	10/19/2011	Anti-Folate Receptor Alpha Antibody Glycoforms
MORR-035-U1RU	Russian Federation	2013122843	10/19/2011	Anti-Folate Receptor Alpha Antibody Glycoforms
MORR-042-P1US	United States	61/647,384	05/15/2012	Methods For Treatment of Gastric Cancer
MORR-042-U1PC	Patent Cooperation Treaty	PCT/US2013/031208	03/14/2013	Methods For Treatment of Gastric Cancer
MORR-042-U1US	United States	14/400,951 9,512,223	11/13/2014 12/06/2016	Methods For Treatment of Gastric Cancer
MORR-042-C1US	United States	15/345,618	11/08/2016	Methods For Treatment of Gastric Cancer
MORR-042-U1BR	Brazil	BR1120140283060	03/14/2013	Methods For Treatment of Gastric Cancer
MORR-042-U1CL	Chile	03088-2014	03/14/2013	Methods For Treatment of Gastric Cancer
MORR-042-U1EP	European Patent Convention	13790637.6	03/14/2013	Methods For Treatment of Gastric Cancer
MORR-042-U1JP	Japan	2015-512637 6122948	03/14/2013 04/17/2017	Methods For Treatment of Gastric Cancer
MORR-042-U1MX	Mexico	MX/a/2014/013931	03/14/2013	Methods For Treatment of Gastric Cancer
MORR-044-P1US	United States	61/837,543	06/20/2013	Methods For Treatment of Ovarian Cancer
MORR-044-U1PC	Patent Cooperation Treaty	PCT/US2014/043402	06/20/2014	Methods For Treatment of Ovarian Cancer
MORR-044-U1US	United States	14/898,905	12/16/2015	Methods For Treatment of Ovarian Cancer
MORR-044-U1AU	Australia	2014284212	06/20/2014	Methods For Treatment of Ovarian Cancer
MORR-044-U1BR	Brazil	BR1120150319505	06/20/2014	Methods For Treatment of Ovarian Cancer
MORR-044-U1CA	Canada	2,914,237	06/20/2014	Methods For Treatment of Ovarian Cancer
MORR-044-U1CO	Colombia	16-012.375	06/20/2014	Methods For Treatment of Ovarian Cancer
MORR-044-U1EP	European Patent Convention	14813679.9	06/20/2014	Methods For Treatment of Ovarian Cancer
MORR-044-U1JP	Japan	2016-521841	06/20/2014	Methods For Treatment of Ovarian Cancer
MORR-044-U1MX	Mexico	MX/a/2015/017950	06/20/2014	Methods For Treatment of Ovarian Cancer
MORR-044-U1PA	Panama	90972	06/20/2014	Methods For Treatment of Ovarian Cancer

Morphotek to Eisai Inc.

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-046-P1US	United States	62/149,184	04/17/2015	Methods For Treating Lung Cancer
MORR-046-U1PC	Patent Cooperation Treaty	PCT/US2016/027497	04/14/2016	Methods For Treating Lung Cancer
MORR-046-U1US	United States	15/566,888	10/16/2017	Methods For Treating Lung Cancer
MORR-046-U1AU	Australia	2016248222	04/14/2016	Methods For Treating Lung Cancer
MORR-046-U1BR	Brazil	BR112017022320-1	04/14/2016	Methods For Treating Lung Cancer
MORR-046-U1CA	Canada	2983126	04/14/2016	Methods For Treating Lung Cancer
MORR-046-U1CN	China	201680028727.8	04/14/2016	Methods For Treating Lung Cancer
MORR-046-U1EP	European Patent Convention	16718820.0	04/14/2016	Methods For Treating Lung Cancer
MORR-046-U1IL	Israel	255079	04/14/2016	Methods For Treating Lung Cancer
MORR-046-U1IN	India	n/a - inactive	04/14/2016	Methods For Treating Lung Cancer
MORR-046-U1JP	Japan	2017-554475	04/14/2016	Methods For Treating Lung Cancer
MORR-046-U1KR	South Korea	10-2017-7032864	04/14/2016	Methods For Treating Lung Cancer
MORR-046-U1MX	Mexico	MX/a/2017/013390	04/14/2016	Methods For Treating Lung Cancer
MORR-046-U1RU	Russian Federation	2017136863	04/14/2016	Methods For Treating Lung Cancer
MORR-046-U1SG	Singapore	11201708546U	04/14/2016	Methods For Treating Lung Cancer
MORR-049-P1US	United States	62/324,920	04/20/2016	Prognosis Of Serous Ovarian Cancer Using Biomarkers
MORR-049-U1PC	Patent Cooperation Treaty	PCT/IB2017/052289	04/20/2017	Prognosis Of Serous Ovarian Cancer Using Biomarkers